Evidence digest
What the research on Selank actually shows
The indexed literature on Selank includes human clinical or observational records (4 human-clinical or observational records). This digest describes the shape of that evidence and links the records behind it. It does not judge whether Selank is safe or effective for any purpose, and nothing here is medical advice — the material sold by the vendors in this index is labeled for laboratory research use only.
Updated 25 Aug 2026 · 4 studies indexed · 4 human · compound record
- Studies indexed
- 4
- Human evidence
- 4
- Preclinical only
- 0
What is and is not established
What the literature supports
- Human clinical or observational records are indexed for Selank (4).
- Published research is indexed back to 2001, with roughly 135 PubMed records located.
- It is listed by one or more vendors tracked in this index.
What is NOT established
- This index does not evaluate whether Selank is safe or effective for any use.
- Material sold by the vendors indexed here is labeled for laboratory research use only and is not a regulator-approved medicine in that form.
- No dosing, protocol or human-use guidance is provided or implied anywhere in this index.
Studies indexed
3 human — controlled trial · 1 human — observational
| Study | Evidence type | Model | n | What it reported | Source |
|---|---|---|---|---|---|
| [Optimization of the treatment of anxiety disorders with selank]Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2015 | Human — controlled trial | Not recorded | — | To compare the efficacy and tolerability of monotherapy with phenazepam to complex treatment with the peptide preparation selank and phenazepam in patients with anxiety disorders. Authors explored the anxiolytic effect and tolerability of monotherapy with phenazepam (30 patients) and complex treatment with selank and phenazepam (40 patients) in anxiety-phobic, hypochondriac and somatoform disorders (ICD-10 items F40.2-9, F41.1-9, F45.0-2). Therapeutic effect was assessed clin… | PMID 26356395 |
| [A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders]Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2014 | Human — controlled trial | Not recorded | — | Objective. To study the efficacy and tolerability of the new anxyolytic peptide selank in comparison with phenazepam. Material and methods. A comparative study of the anxiolytic effect and tolerability of selank and phenazepam was carried out in 60 patients with phobic-anxiety- and somatoform disorders (F40.2-9, F41.1-9, F45.0-1 by ICD-10) were examined. Results Pronounced anxiolytic and mild nootropic effects of selank were demonstrated. The anxiolytic effect lasted for a we… | PMID 25176261 |
| [Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia]Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2008 | Human — controlled trial | Not recorded | — | Sixty-two patients with generalized anxiety disorder (GAD) and neurasthenia were studied. The effect of selank (30 patients) was compared to that of medazepam (32 patients). Patient's state was assessed with psychometric scales (Hamilton, Zung, CGI). Enkephalin activity in the blood serum was measured as well. The anxiolytic effects of both drugs were similar but selank had also antiasthenic and psychostimulant effects. The clinical-biological study revealed that patients wit… | PMID 18454096 |
| Predictive factors of the presence of pulmonary embolism in patients with interstitial lung disease: Observational studyMedicine · 2024 | Human — observational | Not recorded | — | In patients with interstitial lung disease (ILD), the risk of pulmonary embolism (PE) is increased; however, distinguishing between PE and ILD exacerbation can be difficult. Therefore, this study investigated the usefulness of the Wells criteria and revised Geneva score and predictive factors for diagnosing PE in ILD patients with worsening respiratory symptoms. We retrospectively collected the data of 65 patients with ILD who underwent computed tomography pulmonary angiograp… | PMID 38181286 |
Vendors listing Selank
The evidence above describes the published literature. What any individual vial contains is a separate question, answered by that vendor’s certificate records rather than by any study on this page.
| Vendor | Score · Coverage | Certificates | |
|---|---|---|---|
| Curo | 93.877% | 1 | profile → |
| Next Gen Peptides | 93.897% | 3 | profile → |
| Ascend Science | 90.291% | 1 | profile → |
| PeptidePlugs | 89.790% | 3 | profile → |
| American Peptides | 83.6100% | 3 | profile → |
| Northline Labs | 79.493% | 1 | profile → |
| NeuroLabs Research | 79.386% | 1 | profile → |
| Koi Peptides | 79.394% | 1 | profile → |
| ZC Labs | 79.384% | 1 | profile → |
| Good Science Bio | 79.275% | 0 | profile → |
| Ascension Peptides | 78.186% | 1 | profile → |
| Modern Aminos | 74100% | 1 | profile → |
| Simple Peptide | 7489% | 1 | profile → |
| Improved Peptides | 7089% | 0 | profile → |
| Eternal Peptides | 68.265% | 0 | profile → |
| BioLongevity Labs | 67.274% | 0 | profile → |
| Evolve Peptides | 65.567% | 0 | profile → |
| Mile High Compounds | 65.494% | 2 | profile → |
How to read this page
This digest describes what published research exists and what it does not establish. It is not a recommendation, contains no dosing information or protocols, and makes no claim that any compound is safe or effective for any purpose. Material listed by indexed vendors is labeled for laboratory research use only.